Head-to-head
Oak Longevity vs Gala GLP-1
Compared on semaglutide across the eight dimensions this database records. They differ on 5 of those eight. Oak Longevity is cheaper on all-in semaglutide at 2.4 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
Oak Longevity is $133 a month all-in for semaglutide; Gala GLP-1 is $179. Over twelve months that is $1,596 against $2,148. Value Scores are 95.6 and 75.9 out of 100.
Semaglutide
Plan pages: Oak Longevity plans · Gala GLP-1 plans
At 2.4 mg/week, Oak Longevity is $133 a month all-in and Gala GLP-1 is $179 — $46 apart, or $552 across a year. Over twelve months the totals are $1,596 (billed monthly) and $2,148 (billed monthly).
Oak Longevity charges a flat $133 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay.
Gala GLP-1 charges a flat $179 per month for semaglutide at every dose from 0.25 to 2.4 mg per week, so titrating upward does not change what you pay.
| Dose | Oak Longevity | Rank | Gala GLP-1 | Rank | Cheaper |
|---|---|---|---|---|---|
| 0.25 mg | $133 | 4/32 | $179 | 14/32 | Oak Longevity by $46 |
| 0.5 mg | $133 | 3/21 | $179 | 9/21 | Oak Longevity by $46 |
| 1 mg | $133 | 3/21 | $179 | 9/21 | Oak Longevity by $46 |
| 1.7 mg | $133 | 3/21 | $179 | 9/21 | Oak Longevity by $46 |
| 2.4 mg | $133 | 3/29 | $179 | 11/29 | Oak Longevity by $46 |
Oak Longevity is cheaper at every dose where both publish a price, so the lead does not change as you titrate.
Across the 29 programs this database can rank on semaglutide, Oak Longevity sits 2 of 29 on all-in monthly cost and Gala GLP-1 sits 8. There are 5 other programs priced between them. The field median is $249 and the floor is $129, so both sit below the median. Oak Longevity is $4 above the cheapest semaglutide program on record. Gala GLP-1 is $50 above the cheapest semaglutide program on record.
NovoCare Pharmacy (Wegovy), the lowest FDA-approved semaglutide channel here, is $349 a month — Oak Longevity undercuts it by $216, Gala GLP-1 by $170. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | Oak Longevity | Gala GLP-1 | Cheaper |
|---|---|---|---|
| Month to month | $133 | $179 | Oak Longevity by $46 |
| 3-month term | — | $199 | only Gala GLP-1 publishes this term |
| Settled dose | Oak Longevity | Gala GLP-1 | Difference |
|---|---|---|---|
| 0.25 mg | $1,596 | $2,148 | $552 apart |
| 0.5 mg | $1,596 | $2,148 | $552 apart |
| 1 mg | $1,596 | $2,148 | $552 apart |
| 1.7 mg | $1,596 | $2,148 | $552 apart |
| 2.4 mg | $1,596 | $2,148 | $552 apart |
Oak Longevity publishes no rate for 3-month term, 6-month term, 12-month term; Gala GLP-1 publishes none for 6-month term, 12-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 2.4 mg/week, the first twelve months work out to $1,596 on Oak Longevity and $2,148 on Gala GLP-1. Both programs charge one flat rate, so the ramp costs the same as any other stretch of the year.
Value Scores are 95.6 for Oak Longevity and 75.9 for Gala GLP-1, against a semaglutide category floor of $129. Oak Longevity leads by 19.7 points, driven mostly by price.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| Oak Longevity | 67.9 | 12.8 | 10 | 5 | 95.6 |
| Gala GLP-1 | 50.5 | 10.5 | 10 | 5 | 75.9 |
Where the two programs differ
All-in monthly
Oak Longevity is cheaper month to month — $133 against $179, a gap of $46 every month, or $552 across a year if both rates hold.
Cancellation terms
Cancellation differs: Oak Longevity states Cancel before renewal, while Gala GLP-1 states Per provider terms. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
Oak Longevity asks for Month-to-month; Gala GLP-1 asks for 3-month plan or standard monthly; confirm exact terms at enrollment. This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Evidence status
The two prices are not equally well evidenced. Oak Longevity's figure is provider-stated and Gala GLP-1's is reported. Oak Longevity rests on the stronger of the two, and the Value Score below reflects that — evidence quality is worth fifteen points and is not a tiebreaker we apply after the fact.
Twelve-month cost
Over twelve months the totals are $1,596 for Oak Longevity and $2,148 for Gala GLP-1. Oak Longevity is lower by $552 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.
Dose policy
Both hold one price across the whole dose ladder, so neither punishes titration and the monthly figures above are what you actually pay at 15 mg as well as at 2.5 mg.
Membership fee
Neither charges a separate membership fee.
Shipping
Shipping is handled the same way by both — included in the quoted price.
What each record says
Oak Longevity Official site
A small cash-pay telehealth program whose $133/month flat semaglutide price is currently the lowest month-to-month figure in our semaglutide index.
It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacy (not publicly itemized), so who actually makes the medication cannot be independently verified; commitment terms are Month-to-month; cancellation is Cancel before renewal; availability is stated as Availability confirmed at intake.
Evidence: provider-stated — taken from the provider's own published pages; checkout capture pending, captured . Source — First-party pricing page capture 2026-08-08
Watch: Small operator; pharmacy partner not publicly itemized. Price captured from the provider's published pages; checkout capture pending.
Gala GLP-1 Official site
Gala GLP-1 is an all-50-state compounded GLP-1 service offering a range of pricing by product tier, including a microdosing option. Its standard all-dose rate is $179/mo (tirz) and $179/mo (sema) with a microdosing tier starting at $149.
It does not publicly name its compounding pharmacy; the record shows Partner 503A pharmacies (not named publicly), so who actually makes the medication cannot be independently verified; commitment terms are 3-month plan or standard monthly; confirm exact terms at enrollment; cancellation is Per provider terms; availability is stated as All 50 states (per provider claim; confirm at intake).
Evidence: reported — sourced from dated third-party reporting; first-party capture pending, captured . Source — rangeyourself.com, capture 2026-07-14
Watch: Gala lists a range rather than one fixed price: the hero says $179/mo 'all doses', the FAQ says $199/mo 'with a 3-month plan', and $149/mo is listed for microdosing. This makes 'all-in maintenance' ambiguous; we rank on the $179 standard figure with a note. Exact ongoing rate must be confirmed at enrollment. Reported status from RangeYourself 2026-07-14.
Which molecules each one carries
Oak Longevity carries semaglutide at $133 a month; does not offer tirzepatide.
Gala GLP-1 carries tirzepatide at $179 a month and semaglutide at $179 a month.
Comparable only on semaglutide: they do not both publish a rankable tirzepatide price. Switching molecule mid-treatment would mean changing provider.
What neither record tells you
Oak Longevity does not publish
- no published twelve-month semaglutide rate
- no named compounding pharmacy
- no state-by-state availability list — it says Availability confirmed at intake
Gala GLP-1 does not publish
- no published twelve-month semaglutide rate
- no named compounding pharmacy
- no state-by-state availability list — it says All 50 states (per provider claim; confirm at intake)
- no specific cancellation or refund terms
Ask Oak Longevity and Gala GLP-1 for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Evidence may be upgraded. Gala GLP-1 carries a price we have not captured at checkout. A capture would move the evidence term and could reorder these two without any price changing.
Which one suits which reader
On the lowest standing monthly rate for semaglutide, Oak Longevity Official site wins this matchup. And if you would rather trust a better-evidenced number, oak longevity's price rests on stronger provenance.
Both figures should be checked at the provider's own checkout before you pay. Oak Longevity's semaglutide price is provider-stated as of 2026-08-08; Gala GLP-1's is reported as of 2026-07-14.
Questions
Is Oak Longevity or Gala GLP-1 cheaper for semaglutide?
Oak Longevity is cheaper on all-in monthly cost at 2.4 mg/week: $133 against $179, a difference of $46 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of Oak Longevity versus Gala GLP-1?
Oak Longevity works out to $1,596 across twelve months and Gala GLP-1 to $2,148, on the plan terms each publishes.
Does Oak Longevity or Gala GLP-1 raise the price as the dose goes up?
Oak Longevity: no, it charges one flat rate at every dose. Gala GLP-1: no, it charges one flat rate at every dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do Oak Longevity and Gala GLP-1 differ?
5 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of Oak Longevity and Gala GLP-1 names its pharmacy?
Neither. Oak Longevity records Partner 503A pharmacy (not publicly itemized) and Gala GLP-1 records Partner 503A pharmacies (not named publicly). Without a named pharmacy, neither program's licensing or inspection history can be checked before you order.
How well evidenced are the Oak Longevity and Gala GLP-1 prices?
Oak Longevity's semaglutide figure is provider-stated — taken from the provider's own published pages; checkout capture pending — captured 2026-08-08. Gala GLP-1's is reported, captured 2026-07-14. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Official sources: Oak Longevity official site · Gala GLP-1 official site. Compounded tirzepatide and semaglutide are not FDA-approved products.